LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Home・Akciju saraksts・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Slēgts

3.96 -2.22

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.91

Max

4.12

Galvenie mērījumi
By Trading Economics
Ienākumi	-136K -35M
EPS	-0.503
Darbinieki	106
EBITDA	-619K -38M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+72.41% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-5.7M 289M
Iepriekšējā atvēršanas cena	6.18
Iepriekšējā slēgšanas cena	3.96

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 26. maijs 16:52 UTC

Galvenie ziņu notikumi

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

2026. g. 26. maijs 23:57 UTC

Peļņas

Sociedad Quimica 1Q Rev $1.76B >SQM

2026. g. 26. maijs 23:57 UTC

Peļņas

Sociedad Quimica 1Q EPS $1.28 >SQM

2026. g. 26. maijs 23:48 UTC

Tirgus saruna

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

2026. g. 26. maijs 21:54 UTC

Peļņas

Webco Industries 3Q EPS $11.61 >WEBC

2026. g. 26. maijs 21:54 UTC

Peļņas

Webco Industries 3Q Sales $179.6M >WEBC

2026. g. 26. maijs 21:48 UTC

Tirgus saruna

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

2026. g. 26. maijs 21:00 UTC

Tirgus saruna

ESG Roundup: Market Talk

2026. g. 26. maijs 20:58 UTC

Iegādes, apvienošanās, pārņemšana

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

2026. g. 26. maijs 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 26. maijs 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 26. maijs 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 26. maijs 19:22 UTC

Tirgus saruna

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

2026. g. 26. maijs 19:17 UTC

Tirgus saruna

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

2026. g. 26. maijs 18:56 UTC

Tirgus saruna

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

2026. g. 26. maijs 18:03 UTC

Tirgus saruna

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

2026. g. 26. maijs 17:42 UTC

Tirgus saruna

Grains Await Fresh Trading Catalyst -- Market Talk

2026. g. 26. maijs 17:33 UTC

Tirgus saruna

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

2026. g. 26. maijs 17:21 UTC

Tirgus saruna

Canada Faces a Labor Market Squeeze -- Market Talk

2026. g. 26. maijs 16:52 UTC

Tirgus saruna

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

2026. g. 26. maijs 16:43 UTC

Tirgus saruna

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

2026. g. 26. maijs 16:24 UTC

Tirgus saruna

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

2026. g. 26. maijs 16:21 UTC

Tirgus saruna

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

2026. g. 26. maijs 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 26. maijs 16:20 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2026. g. 26. maijs 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 26. maijs 16:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Auto & Transport Roundup: Market Talk

2026. g. 26. maijs 16:16 UTC

Tirgus saruna

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

2026. g. 26. maijs 16:01 UTC

Tirgus saruna

Bitcoin Lower as Stress Builds for Holders -- Market Talk

2026. g. 26. maijs 15:21 UTC

Tirgus saruna

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

72.41% augšup

Prognoze 12 mēnešiem

Vidējais 7 USD 72.41%

Augstākais 10 USD

Zemākais 4 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

7 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 7 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.